Aspire Biopharma Holdings, Inc. entered into a securities purchase agreement with select institutional and accredited investors for a private placement of up to $21.0 million of Series A Convertible Preferred Stock, priced at $800 per share. The company completed an initial closing of $11.0 million, with a second closing expected subject to customary conditions. Proceeds are intended to support balance sheet restructuring, regain Nasdaq stockholders’ equity compliance, reduce indebtedness, and advance the company’s patent-pending drug delivery technologies.
RBW Capital Partners LLC, through Dawson James Securities, Inc., served as sole placement agent, with Lucosky Brookman LLP acting as placement agent counsel.
